{"id":"NCT04058158","sponsor":"Samsung Bioepis Co., Ltd.","briefTitle":"A Study to Compare SB12 (Proposed Eculizumab Biosimilar) to Soliris in Subjects With Paroxysmal Nocturnal Haemoglobinuria","officialTitle":"A Phase III Randomised, Double-blind, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB12 (Proposed Eculizumab Biosimilar) and Soliris® in Subjects With Paroxysmal Nocturnal Haemoglobinuria","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-08-07","primaryCompletion":"2021-09-21","completion":"2021-10-21","firstPosted":"2019-08-15","resultsPosted":"2024-03-26","lastUpdate":"2024-03-26"},"enrollment":50,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Paroxysmal Nocturnal Hemoglobinuria"],"interventions":[{"type":"DRUG","name":"SB12 (proposed eculizumab biosimilar)","otherNames":[]},{"type":"DRUG","name":"Soliris (eculizumab)","otherNames":[]}],"arms":[{"label":"Treatment Sequence I","type":"EXPERIMENTAL"},{"label":"Treatment Sequence II","type":"EXPERIMENTAL"}],"summary":"This is a randomised Phase III, double-blind, multicentre, cross-over study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB12 and Soliris® in subjects with PNH.","primaryOutcome":{"measure":"Lactate Dehydrogenase (U/L) at Week 26","timeFrame":"Week 26","effectByArm":[{"arm":"SB12","deltaMin":284.2,"sd":456.73},{"arm":"Soliris","deltaMin":249.72,"sd":103.67}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":6},"locations":{"siteCount":27,"countries":["India","Malaysia","Mexico","Romania","South Korea","Taiwan","Thailand","Ukraine"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":47},"commonTop":["Corona virus infection","Haemoglobinuria","Diarrhoea","Alanine aminotransferase increased","Headache"]}}